Blocking 5-LO pathway alleviates renal fibrosis by inhibiting the epithelial-mesenchymal transition

Jian Zhou,Rui Li,Qinhui Liu,Jinhang Zhang,Hui Huang,Cuiyuan Huang,Guorong Zhang,Yingnan Zhao,Tong Wu,Qin Tang,Ya Huang,Zijing Zhang,Yanping Li,Jinhan He

DOI: https://doi.org/10.1016/j.biopha.2021.111470

2021-06-01

Abstract:<p>The enzyme 5-lipoxygenase (5-LO) converts arachidonic acid to leukotrienes, which mediate inflammation. The enzyme is known to contribute to organ fibrosis, but how it contributes to renal fibrosis is unclear. Here, we reported that fibrotic kidneys expressed high levels of 5-LO, and deleting the 5-LO gene mitigated renal fibrosis in mice subjected to unilateral ureteral obstruction (UUO), based on assays of collagen deposition, injury and inflammation. Mechanistically, the exogenous leukotrienes B₄ and C₄, the downstream products of 5-LO, could induce the epithelial-mesenchymal transition (EMT) in kidney epithelial cell cultures, based on assays of E-cadherin, vimentin and snail expression. Studies in UUO mice confirmed that 5-LO deletion inhibited the EMT in the obstructed kidney. More importantly, 5-LO inhibitor zileuton loaded in CREKA-Lip, which could target to fibrotic kidney, markedly attenuated UUO-induced renal fibrosis and injury by inhibiting the EMT in the obstructed kidney. Our results suggested that 5-LO activity may contribute to renal fibrosis by promoting renal EMT, implying that the enzyme may be a useful therapeutic target.</p>

pharmacology & pharmacy,medicine, research & experimental